SCHEMBL17192040

SCHEMBL17192040

COc1ccc(COc2cc3ncn(CCN4CCCC4)c(=O)c3c(Cl)c2OCc2ccc(OC)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.46
ALDH1A1 P00352 4/20 0.46
HSD17B10 Q99714 2/20 0.46
HPGD P15428 3/20 0.45
GLA P06280 2/20 0.45
GAA P10253 2/20 0.45
MEN1 O00255 1/20 0.45
MAPT P10636 1/20 0.45
KMT2A Q03164 1/20 0.45
RCE1 Q9Y256 1/20 0.45
TNF P01375 1/20 0.44
MCHR1 Q99705 2/20 0.42
KCNH2 Q12809 1/20 0.42
HRH3 Q9Y5N1 2/20 0.41
CSF1R P07333 1/20 0.39
PREP P48147 1/20 0.39
LTA4H P09960 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA1D P25100 1/20 0.38
HTR1B P28222 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15671101 0.95 TNF (0.47) KDM4EALDH1A1HSD17B10HPGDGLA
SCHEMBL17181483 0.88 TNF (0.47) KDM4ETNFCSF1RP2RX3
SCHEMBL17181536 0.87 TNF (0.51) KDM4EALDH1A1GAAMAPTTNF
SCHEMBL15670882 0.83 SYK (0.42) KDM4EALDH1A1GAAMEN1MAPT
SCHEMBL15680656 0.83 KDM4E (0.52) KDM4EALDH1A1HSD17B10HPGDGLA
SCHEMBL17181555 0.82 TNF (0.39) KDM4EGAAMEN1MAPTKMT2A
SCHEMBL17181429 0.81 TNF (0.38) ALDH1A1KMT2ATNFCSF1RPREP
SCHEMBL17192037 0.78 KCNH2 (0.44) KDM4EALDH1A1HSD17B10HPGDGLA
SCHEMBL15680502 0.75 CSF1R (0.40) KDM4EALDH1A1HSD17B10HPGDGAA
SCHEMBL15671495 0.75 TNF (0.43) KDM4EALDH1A1HSD17B10HPGDGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10174053-B2 2 substituted cephem compounds GLAXO GROUP LIMITED (GB) 2019-01-08 US disclosed
US-20170281532-A1 2 SUBSTITUTED CEPHEM COMPOUNDS GLAXO GROUP LIMITED (GB) 2017-10-05 US disclosed
US-20170281532-A1 2 SUBSTITUTED CEPHEM COMPOUNDS GLAXO GROUP LIMITED (GB) 2017-10-05 US disclosed
US-20150299223-A1 2-SUBSTITUTED CEPHEM COMPOUNDS GLAXO GROUP LTD (GB) 2015-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281532-A1 2 SUBSTITUTED CEPHEM COMPOUNDS CEP170, CES2, CMBL KDM4E 1724/4885ALDH1A1 1437/4885HSD17B10 716/4885
US-20150299223-A1 2-SUBSTITUTED CEPHEM COMPOUNDS CEP170, ABL1, CEPT1 KDM4E 2208/4885ALDH1A1 3320/4885HSD17B10 1796/4885
US-10174053-B2 2 substituted cephem compounds CEP170, CES2, CMBL KDM4E 1724/4885ALDH1A1 1437/4885HSD17B10 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.